Bank of New York Mellon Corp increased its holdings in Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) by 16.5% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 23,260 shares of the company’s stock after buying an additional 3,299 shares during the period. Bank of New York Mellon Corp owned about 0.10% of Aquinox Pharmaceuticals worth $327,000 as of its most recent filing with the SEC.

Separately, Geode Capital Management LLC boosted its holdings in shares of Aquinox Pharmaceuticals by 10.0% in the 1st quarter. Geode Capital Management LLC now owns 121,532 shares of the company’s stock valued at $2,028,000 after buying an additional 11,035 shares during the period. Hedge funds and other institutional investors own 95.15% of the company’s stock.

Several research analysts have recently commented on the stock. Zacks Investment Research lowered shares of Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. ValuEngine lowered shares of Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 15th. Canaccord Genuity set a $22.00 price target on shares of Aquinox Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, August 8th. Finally, BidaskClub raised shares of Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 4th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. Aquinox Pharmaceuticals has an average rating of “Hold” and a consensus price target of $22.25.

WARNING: This piece was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at

Aquinox Pharmaceuticals (NASDAQ:AQXP) last announced its quarterly earnings data on Tuesday, August 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.59).

Aquinox Pharmaceuticals Profile

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.

Want to see what other hedge funds are holding AQXP? Visit to get the latest 13F filings and insider trades for Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP).

Institutional Ownership by Quarter for Aquinox Pharmaceuticals (NASDAQ:AQXP)

Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.